An impaired function of alveolar surfactant can cause lung transplant dysfunction early after reperfusion. In this study it was investigated whether treatment with surfactant before reperfusion improves the immediate function of lung transplants and whether an improved transplant function was associated with an increase in alveolar surfactant components. Left lungs with 6-hour (n=8) or prolonged 20-hour ischemia (n=10) were transplanted syngeneically in rats. In both ischemia groups half of the lung transplants were treated with surfactant just before reperfusion. Lung function was measured during reperfusion for 1 hour. Thereafter, the rats were killed and bronchoalveolar lavage was performed to measure alveolar surfactant components. We found that surfactant treatment improved the immediate function of lung transplants in parallel with a higher amount of total surfactant phospholipids, a higher percentage of the heavy subtype of surfactant, a normalized percentage of phosphatidylcholine, and a higher amount of endogenous surfactant protein-A. We conclude that surfactant treatment before reperfusion does improve the immediate lung transplant function in rats in association with an increase in alveolar surfactant components. More particularly, the amount of (endogenous) SP-A is thought to be crucial for the efficacy of surfactant treatment after lung transplantation. In normal lungs, surfactant reduces the surface tension at the air-fluid interface and thereby preventing an alveolar collapse at end-expiration. To fulfill this function, surfactant is composed of a complex mixture consisting of mainly phospholipids and at least three surfactant proteins (SP), SP-A, SP-B, and SP-C (1, 2) After lung transplantation, the ischemia-reperfusion injury causes an impaired function of alveolar surfactant (3, 4) similar to the impairment found with acute respiratory distress syndrome (ARDS) (5). Early after reperfusion of the transplants three specific surfactant components, each having a specific role in surfactant function, were found to be decreased, namely: the amount of phosphatidylcholine (PC) (4), the major class of surfactant phospholipids that forms the surface-tension-reducing monolayer (1); the percentage of heavy subtype surfactant (or large aggregates) (3) that contains tubular myelin, which is the surfactant structure from which the surfactant phospholipids can adsorb into the air-fluid interface (6): and the amount of SP-A (3), which regulates the adsorption process of the phospholipids (7). Furthermore, SP-A is essential in the formation of tubular myelin (8), being involved in the control of secretion and re-uptake of surfactant by the type II pneumocytes (9, 10), and minimizing the inhibition of surfactant by leaked serum proteins Surfactant treatment improves the lung transplant function 65 (11). The function of surfactant in the injured lung transplants was shown to be further inhibited by serum proteins, which leak, in large amounts into the alveolar fluid (3, 4). It was concluded that this impaired function of surfactant contributes significantly to the dysfunction of transplanted lungs during the early reperfusion period (3, 4).
. The function of surfactant in the injured lung transplants was shown to be further inhibited by serum proteins, which leak, in large amounts into the alveolar fluid (3, 4) . It was concluded that this impaired function of surfactant contributes significantly to the dysfunction of transplanted lungs during the early reperfusion period (3, 4) .
To improve the immediate function of transplanted lungs it would be sensible to explore treatments which can restore the function of alveolar surfactant. Intratracheal surfactant treatment could be a possibility. Surfactant treatment has been shown to improve lung function in various acute lung injury models and in human ARDS (12, 13, 14, 15) In lung transplantation, one experimental study in dogs showed a positive effect of early surfactant treatment on gas exchange. However, an improvement in lung transplant function was found only with a small percentage of the surfactant-treated animals (16) , possibly due to the extremely long 38-h ischemia period .
In the present study two questions concerning the effect of surfactant treatment in lung transplantation were investigated. First, does surfactant treatment before reperfusion improve the immediate function of lung transplants after a 6-h or a prolonged 20-h ischemia period and subsequent reperfusion? Second, is an improved function of lung transplants associated with an increase in alveolar surfactant components, which are known to be important to alveolar surfactant function? Therefore the function of left lung transplants during a 1-h reperfusion period was measured in rats, with or without instillation of surfactant. After this 1-h reperfusion period, components of alveolar surfactant and variables of lung injury were measured in bronchoalveolar lavage fluid (BALF).
Materials and methods

Experimental groups
Inbred rats (LEW strain, male, 240 to 320 g) were used as donors, recipients, sham-operated, and non-operated, normal, animals. All animals received humane care in compliance with the Dutch regulations and law. Left lungs were transplanted to rats of the following groups: 6-h ischemia, either with or without surfactant treatment ( four each ), and 20-h ischemia either with or without surfactant treatment ( five each ). Rats that were ventilated and sham operated with a left sided thoracotomy only were used as controls of lung function values ( sham, n=4 ), while non operated, normal rats were used as controls of values in BALF ( normal, n=4 ).
similarly but air instead of surfactant was instilled. Treatment with saline vehicle alone was not used as a control since this provoked severe and fatal pulmonary edema in pilot experiments. Surfactant was administered at 0.2 ml doses followed by an air bolus of 0.5 ml to enhance the spread of surfactant. During instillation, the left main bronchus was tied with a ligature around the cannula to prevent air and surfactant leaking into the trachea. After the cannula was withdrawn, the ventilation settings were changed to 24 cm H 2 O PIP, 5 cm H 2 O PEEP, and 55 breaths per minute. The left lung was ventilated without reperfusion for 1 minute to facilitate the surfactant-spread before the onset of reperfusion injury. Reperfusion of the lung transplant was allowed, by first releasing the clip at the pulmonary vein followed by releasing the clip at the pulmonary artery.
Lung transplant function
Transplant function was measured during a 1-h reperfusion period at t = 10, 25, 40, and 60 minutes. Transplant function was assessed by measuring PO 2 and PCO 2 in blood drawn from the left pulmonary vein and by measuring blood flow in the left pulmonary artery. In addition, dynamic compliance of both lungs was recorded at fixed pressures at t = 60 minutes. Five minutes before a blood gas sample was taken, excessive lung fluids were suctioned from the tube and trachea and PIP was increased to 30 cm H 2 O during four breaths to expand the lung completely. PO 2 and PCO 2 were measured with a blood gas analyzer (ABL 330, Radiometer, Copenhagen, Denmark). The blood flow was measured with an ultrasound method ( 1-mm probe [1RB], Transonic Systems Inc., Ithaca, NY ). The flow probe was placed round the pulmonary artery immediately after the blood samples for the PO 2 and PCO 2 were drawn and it was removed after each measurement. Dynamic compliance of both lungs at 5 cm H 2 O PEEP and 24 cm H 2 O Pmax was calculated as follows: volume at Pmax x 24 cm H 2 O -1 x [(kg BW donor + kg BW recipient)/ 2]-1. Even though the dynamic compliance of both lungs may not be the most sensitive measure for the function of the left lung transplant, as both left and right lung are measured simultaneously, differences in dynamic compliance between separate groups can be ascribed to changes in the left lung transplant. To measure control values of lung function rats were sham-operated in a way similar to the recipient rats but without transplantation of a lung. Blood for PO 2 and PCO 2 was drawn from the left ventricle instead of the left pulmonary vein, and for blood flow measurements only the pulmonary artery was dissected and not the complete lung hilus. Ten minutes after the ventilator was set, as described in Surfactant treatment , measurement of PO 2 , PCO 2 , blood flow, and the dynamic compliance was performed.
Bronchoalveolar lavage (BAL)
After the 1-h reperfusion period the rats were killed by bleeding the animals. Heart and lungs were taken out en-bloc. Left and right lungs were lavaged separately as described previously (4) , except that saline stored on ice was used to lavage the lungs. Collection of BALF was performed on ice as well and the total volume recovered was recorded. The recovered BALF volume per kg BW did not differ between the groups (on average 53 ml/kg BW for left lungs). The BALF was centrifuged at 150 g for 10 min. at 4 o C to remove cells and cell-debris. The remaining cell-free BALF was used for all further determinations of BALF.
Components of alveolar surfactant
To assess alveolar surfactant function irrespective of the amount of leaked serum protein, four components of alveolar surfactant were determined in BALF: the amount of total surfactant phospholipids, the percentage of heavy subtype surfactant, the percentage PC of total phospholipids, and the amount of endogenous SP-A. Furthermore, we measured the capacity of recovered surfactant to lower surface tension in vitro. The amount of total phospholipid was calculated by summing up the amount of phospholipids in the separated light and heavy subtype fractions. Heavy and light subtypes were separated by centrifuging a 1-ml sample of S1 at 40,000 g for 15 minutes (Beckman TLA-100.3 rotor). After centrifugation the supernatant (S2) contains the light subtype and the pellet (P2) the heavy subtype. Both S2 and P2 were extracted with chloroform and methanol (18) to measure phospholipid contents (19) . The remainder of BALF was centrifuged overnight at 100,000 g, 4 o C, to concentrate the surfactant in a pellet (P3) for the determination of the phospholipid-composition. The phospholipids were separated by thin layer chromatography according to Touchstone and coworkers (20) with the use of their solvent E .The amount of SP-A was assessed in BALF with a sandwich ELISA method (21) . The measured amounts of SP-A do represent endogenous SP-A of the lung transplants, since the surfactant used did not contain SP-A.
In vitro surfactant function
Surface tension measurements were performed only in the 20-h ischemia group because, unfortunately, surfactant of the untreated 6-h ischemia group was lost. The surfactant of P3 was extracted with chloroform and methanol, precipitated with acetone at -20 o C overnight, dried under nitrogen and resuspended in 0.9 % NaCl with 20 milimolars CaCl 2 to a final concentration of 2 mg of phospholipids/ml. The extraction removes inactivating serum proteins as well as hydrophilic surfactant protein SP-A; the acetone precipitation removes neutral lipids. Thus, the remaining surfactant contained only phospholipids and the hydrophobic surfactant proteins, SP-B and SP -C. The resuspended surfactant was incubated at 37 o C for at least 90 minutes before surface tension was analyzed in a pulsating bubble surfactometer (Electronetics Corporation, Amherst, NY) (22) . This apparatus forms a bubble in the surfactant suspension that pulsates at 20 pulsations per minute, with a radius between 0.55 mm (Rmax) and 0.4 mm (Rmin) at 37 o C. The difference in pressure over the suspension/air interface (D P) is measured during each pulsation. The surface tension (g) can be calculated with the law of Laplace(D P = 2g /R). The minimum surface tension, obtained after 20 pulsations, was used as a measure of the in vitro surfactant function
Variables of lung injury
Due to endothelial and epithelial cell injury caused by the ischemia-reperfusion injury of the lung serum proteins leak into the alveoli. To assess the amount of leaked serum proteins, the total amount of proteins was measured in BALF by means of a modified Lowry method (23) . As an indicator of injury to the lung epithelial cells, the lactate dehydrogenase (LDH) activity in BALF was measured spectrophotometrically at 340 nanometers (nM) in 100 µl (24) .
Statistical analysis
All data represent the mean of individual measurements ± SD. For comparison between data from the separate groups, single factor analysis of variance was performed. Differences with a p value of < 0.05 were considered statistically significant. Figure 1 . Improved function of lung transplants after surfactant treatment. Variables measured are shown from top to bottom: PO 2 and PCO 2 in the left pulmonary vein, and blood flow in the left pulmonary artery during the 1-h reperfusion period. Data are given as the mean ± SD. Generally, PO 2 and PCO 2 improved after surfactant treatment (* p < 0.05). In the 6-h ischemia group, the treated group functioned better than those in the 20-h ischemia group ( † p < 0.05).
Results
Lung transplant function during 1-h of reperfusion
Surfactant treatment markedly improved the immediate function of lung transplants in the 6-h ischemia group, whereas lung function was less improved in the 20-h ischemia group. This improved lung function caused by surfactant treatment in the 6-h ischemia group was exemplified by the seven fold increase in PO 2 , accompanied by the two fold decrease in PCO 2 in the left pulmonary vein during reperfusion (Figure 1) , and the 20 % increase in dynamic compliance of both lungs at 60 minutes of reperfusion (Table 1) . Blood flow in the left pulmonary artery was not affected significantly by surfactant treatment (Figure 1 ). In the 20-h ischemia group surfactant treatment resulted in just a slight improvement in PO 2 and PCO 2 during reperfusion, along with a 13 % increase in the dynamic compliance of both lungs at 60 minutes of reperfusion. Dynamic compliance of both lungs after 1 h reperfusion*.
Components of alveolar surfactant
The improved function of lung transplants after surfactant treatment was associated with an increase in the alveolar surfactant components . More specifically, a higher amount of total surfactant phospholipids (Figure 2 A) , a higher percentage of heavy subtype surfactant (Figure 2 B ) , a normalized percentage of PC (Table 2) , and a higher amount of endogenous SP-A ( Figure  3 ) were found in surfactant-treated lungs. All the alveolar surfactant components, with the exception of percentage of PC, were higher in the surfactant-treated 6-h ischemia group than in the 20-h ischemia group. Furthermore, the amount of endogenous SP-A in relation to that of surfactant phospholipids, the SP-A /surfactant phospholipid ratio, was significantly higher in the 6-h than in the 20-h ischemia group (4.7 ± 1.7 and 1.8 ± 0.5 µg/µmol, respectively, p < 0.05 ).
In vitro surfactant function
Minimum surface tension of the extracted surfactant from the 20-h ischemia group after surfactant treatment equaled normal minimum surface tension ( 0.8 ± 0.6 and 0.7 ± 0.6 mN.m -1, respectively). In the untreated 20-h ischemia group, minimum surface tension was as high as 20.1 ± 9.6 mN.m -1, reflecting an impaired in vitro surfactant function, even in the absence of inhibiting serum proteins. 
Lung injury
After surfactant treatment, the amount of serum proteins and LDH activity in BALF revealed separate changes in the two ischemia groups. In the 6-h ischemia group, the amount of protein in BALF remained high after surfactant treatment, whereas LDH activity was normal (Table 3 ). In the 20-h ischemia group surfactant treatment reduced neither the amount of serum protein nor LDH activity in BALF. 
Native right lungs
In native right lungs most of the variables measured were normal; the ischemic period of the contra lateral lung transplant and surfactant treatment had little or no influence (data not shown). The only changes observed in BALF of right lungs were an increase in the amount of proteins in all transplanted rats, indicating some form of injury to the right lungs as a result of the transplantation procedure, and an increase in the amount of surfactant phospholipids in the surfactant-treated rats, most probably caused by a spillover of the surfactant instilled in the left lung.
Discussion
This study shows that surfactant treatment before reperfusion improves lung transplant function during a 1-h reperfusion period after left lung transplantation in rats. Surfactant treatment of lung transplants exposed to a 6-h ischemia period markedly improved gas exchange and increased dynamic compliance. In lung transplants exposed to a prolonged 20-h ischemia period, the effects of surfactant treatment on transplant function were less marked: gas exchange was only slightly improved and dynamic compliance showed just a small increase compared with untreated lung transplants. Furthermore, this study shows that improvement in the function of lung transplants by means of surfactant treatment is closely associated with an improved alveolar surfactant composition, that is, higher amounts of alveolar surfactant components that are known to be important for a good surfactant function. Surfactant treatment increased the amount of surfactant phospholipids, the percentage of heavy subtype surfactant and PC, and the amount of endogenous SP-A in the 6-h as well as the 20-h ischemia group. In general, the effect of surfactant treatment was most apparent in the 6-h ischemia group compared with the 20-h ischemia group.
The higher values of alveolar surfactant components in the surfactanttreated lung transplants may have resulted in a better function of alveolar surfactant in several ways. First, a higher amount of surfactant phospholipids can overcome inactivation of surfactant by leaked serum proteins more effectively, even though inactivation of surfactant by albumin was disputed when tested in vitro at pH values of alveolar lining fluid (25) . Yet, from other studies it was concluded that inactivation of surfactant by serum proteins did occur in vivo and could be prevented by increasing the amount of surfactant instilled (12, 26, 27) . Second, a higher percentage of heavy subtype surfactant is shown to represent a better quality of surfactant, and therefore this parameter has been used as an indicator of the alveolar surfactant function in other studies of acute lung injury (3, 28) . Third, a normalized percentage of PC, the di-saturated species of which form the essential surface-active phospholipids, may contribute to an improved surfactant function. The relevance of these phospholipid surfactant components to the function of surfactant is confirmed by our in vitro surfactant function measurements: the function of extracted surfactant from the untreated 20-h ischemia group was poor but improved significantly after normalization of its composition by surfactant treatment.
Unexpectedly, the amount of endogenous SP-A proved to be the fourth component of surfactant that was higher after surfactant treatment. Considering that SP-A has been found to increase both the percentage of heavy subtype surfactant (8) and its surface activity (7, 29) the higher amount of endogenous SP-A contributed presumably to a better alveolar surfactant function in such a way. In addition, SP-A is a most important component in prohibiting the inactivation of surfactant by serum proteins (2, 11) . That endogenous SP-A does indeed improve the in vivo function of instilled surfactant was described by Ikegami and colleagues (30). Endogenous SP-A was found to associate with the surfactant used for treatment. This association resulted in an improved function of surfactant in vivo as exemplified by an improved lung function in a premature rabbit model. In analogy, we hypothesize that in the surfactant-treated lung transplant the preserved endogenous SP-A associates with the surfactant instilled, thereby improving the function of alveolar surfactant.
The way in which lung transplantation and subsequent surfactant treatment may affect SP-A was not investigated in this study. Other acute lung injury studies that focused on SP-A have shown that SP-A is degraded by oxidation (31, 32) and proteases (31, 33). Therefore, the preserved amount of SP-A after surfactant treatment, as found in this study, might indicate that instilled surfactant diminishes SP-A degradation in lung transplantation.
It seems logical to attribute the improved function of lung transplants after surfactant treatment, as found in this study, to an improved alveolar surfactant function, even though no absolute proof for this statement can be given. Still, lung function may fail to respond favorably to surfactant treatment in case an extended ischemia period has caused serious ischemia-reperfusion injury. Such a serious ischemia-reperfusion injury could explain the failure of surfactant treatment in most transplanted lungs of dogs after an extremely long ischemia period of 38 hours, as used in a study by Novick and colleagues (16) . In the present study too, the effect of surfactant treatment was much weaker after a 20-h than after a 6-h ischemia period. The most striking difference between these two groups was the amount of SP-A, which remained very low after the 20-h ischemia period. Therefore, we assume that preserving the amount of SP-A is of essential importance to substantiate a considerable effect of surfactant treatment in seriously injured lungs.
A small amount of the surfactant instilled was recovered from the surfactant-treated lungs, namely 9.8 % and 4.9 % after 6 and 20-h ischemia, respectively. This low recovery might be caused by a high loss of the surfactant instilled due to the tracheal suctioning to remove excessive pulmonary edema fluid during reperfusion. It is feasible that the surfactant instilled was diluted with the edema fluid and suctioned away, but unfortunately, the surfactant contents of the fluid suctioned were not measured. Alternatively, the low recovery of surfactant might have been caused by its being trapped in hyaline membranes that are formed in the alveoli as a result of epithelial damage (34), which may have been most severe in the 20-h ischemia group.
The assumption that prolongation of cold ischemia time aggravates lung injury is supported by our finding that lung transplants with the shortest ischemia period benefited most from surfactant treatment. However, the amount of protein and LDH activity in BALF from untreated lung transplants did not indicate a difference in the severity of lung injury after a 6 or a 20-h ischemia period. Presumably, the amount of protein in BALF can only be used to discriminate between much milder injuries but not between the severe lung injuries found in transplanted lungs, as indicated by the already considerable protein increase in BALF from the milder injured native right lungs. The LDH activity in BALF might not be a useful measure because it reflects the amount of actual disrupted cells, while the difference in injury to the cells is presumably more subtle.
The efficacy of surfactant treatment might be improved by introducing some changes in the strategy of surfactant treatment. One improvement might be to instill surfactant earlier than just before reperfusion, that is, already in the donor. In this way the surfactant instilled may be already 'activated' in the donor by endogenous components of surfactant, such as SP-A (30). Even though the clinical application of this strategy will not be easy, experimentally it is a most interesting option. Another improvement might be to add SP-A to surfactant. One study, in premature rabbits suffering from respiratory distress syndrome showed that adding SP-A to surfactant improved the effect of treatment (35). The present study indicates that addition of SP-A to surfactants may be worthwhile also after lung transplantation.
Conclusion
This study shows that surfactant treatment before reperfusion improves immediate function of lung transplants in rats even when the ischemia period of the transplant is as long as 20 hours. This improved function of lung transplant due to surfactant treatment was found to be associated with an increase in the components of alveolar surfactant. Of these components the amount of (endogenous) SP-A is thought to be crucial to obtain a favorable effect of surfactant treatment after lung transplantation. Because generally SP-A is not included in surfactants used for treatment, we speculate that addition of SP-A to surfactant may further improve the efficacy of surfactant treatment in lung transplantation. 
Abstract
We investigated whether pulmonary surfactant in rat lung transplants recovered during the first week post-transplantation, in parallel with symptoms of the reimplantation response, and whether this recovery was affected by early surfactant treatment. The severity of transplantation injury was varied by transplanting left lungs with 6 hour and 20 hour ischemia ( n = 12 and 19, respectively ). Half of the transplants were treated by instillation of surfactant before reperfusion. Lungs from sham operated and normal rats (n = 4 and 5, respectively ) served as controls. The transplantation injury severely impaired lung transplant function; ten of the worst affected animals died. After one week symptoms of reimplantation response and properties of pulmonary surfactant were assessed. If untreated, the reimplantation response had almost resolved in the 6-h but not in the 20-h ischemia group; pulmonary surfactant, however, continued to be deficient in both ischemia groups ( low amounts of surfactant phospholipids and surfactant protein A [SP-A] ). Surfactant treatment improved the recovery from injury in the 20-h ischemia group resulting in normal lung function and amounts of surfactant phospholipids. Amounts of SP-A were not improved by surfactant treatment. In conclusion, early surfactant treatment enhances recovery from transplantation injury and is persistently beneficial for pulmonary surfactant in lung transplants. Pulmonary surfactant is a complex mixture of phospholipids and proteins excreted into the fluid lining the alveoli of the lung (1) . Its main function is to lower the surface tension of the fluid layer. A low surface tension prevents that alveoli collapse at end-expiration and also that alveolar edema is formed. In addition, surfactant plays a role in host defense against invading microorganisms (2, 3) .
Immediately after lung transplantation in animals, pulmonary surfactant is affected in its composition and biophysical function (4) (5) (6) . While the total amount of surfactant phospholipids remains constant after lung transplantation, its composition changes unfavorably in at least three aspects: the proportion of surface-active heavy subtype surfactant, the percentage of phosphatidylcholine (PC) in the phospholipids, and the amount of surfactant protein A (SP-A) decrease. The function of this altered surfactant has been shown to be impaired when tested in vitro for its capacity to reduce the surface tension at an air/fluid interface (4-6). In the transplanted lung, this poor biophysical function of surfactant is inhibited additionally by serum proteins leaked into the alveolar space (5) .
The changes of surfactant result from the acute injury inflicted upon the lungs during the transplantation procedure. Amongst other factors, ischemia-reperfusion is generally considered to be most damaging for transplants (7) . Prolonging the ischemia time leads to more severe lung injury (8) , with progressive effects on surfactant and lung function (4) (5) (6) . In clinical lung transplantation, the injury is recognized as diffuse roentgenographic infiltrates, protein rich lung edema, and decreased gas exchange and decreased lung compliance. This syndrome is referred to as the reimplantation response (9) .
Treatment with exogenous surfactant, instilled before reperfusion into lung transplants, has been shown to improve pulmonary surfactant as investigated for a few hours after reperfusion (6, 10) . The surfactant treatment increased the total amount of phospholipids (6), the proportion of surfaceactive heavy subtype (6, 10) and the percentage of PC to normal or supranormal values and it preserved the amount of SP-A (6). As a result of these improvements in composition also the in vitro biophysical function of surfactant was improved (6) . Early surfactant treatment also improved the function of the lung immediately after transplantation.
All studies on pulmonary surfactant in lung transplants have focused on the first few hours after transplantation but recovery of surfactant composition and function on a longer term is expected to be important for both lung transplant function and host defense. It is yet unknown whether altered surfactant recovers from the transplantation injury during the first posttransplantation week, in parallel with the symptoms of the reimplantation response (9), and whether this recovery is affected by early surfactant treatment.
These two questions were investigated in this study by transplanting left lungs syngeneically in rats. The severity of transplantation injury was varied by using a 6 and a 20-hour lung ischemia period. For comparison, a shamoperated group without transplantation or ischemia-reperfusion but with injury caused by the surgical procedures in the recipient was included. Surfactant was instilled into half of the transplanted lungs in each ischemia group. During one week, lung transplants were investigated for recovery from injury, and at the end of this week, for lung function and for amount, composition, and function of its pulmonary surfactant.
Materials and methods
Experimental groups
Inbred rats (LEW strain, specific-pathogen free, male, weighing 240-300 g) were used for donors, recipients, sham-operated, and normal animals. All animals received humane care in compliance with the Dutch regulations and law. Left lungs were transplanted syngeneically to avoid influence of rejection or immunosuppressive treatment. Lungs from six experimental groups were investigated for recovery from transplantation injury and for properties of pulmonary surfactant.: 1) transplanted after 6 hours ischemia (untreated 6-h, n = 6), 2) transplanted after 20 hours ischemia (untreated 20-h, n = 10 ), 3) transplanted after 6 hours ischemia plus surfactant treatment (surfactanttreated 6-h, n = 6), 4) transplanted after 20 hours ischemia plus surfactant treatment (surfactant-treated 20-h, n = 9 ), and as controls, 5) sham-operated rats without ischemia-reperfusion but with the effects of left sided thoracotomy, preparation of pulmonary artery and mechanical ventilation (sham, n = 4), and 6) normal, non-operated rats (normal, n = 5).
Lung transplantation and surfactant treatment
Left lung transplantation was performed as previously described (5) . For harvesting the left lung from the donor, the left pulmonary artery was flushed with 25 ml cold (8 0 C) saline at 40 cm water pressure while the lung was ventilated with a positive end expiratory pressure (PEEP) of 4 cm H 2 O. After dissection of the left main bronchus the lung was allowed to deflate. Then the lung was submersed in 8 0 C saline and placed in the refrigerator at 8 0 C for 5 or 19 hours. One hour before the planned start of reperfusion the lung was taken out of the refrigerator and covered by a sheet of thin plastic.
The recipient rat was anesthetized with a mixture of fluothane (1-2 %), N 2 O and oxygen, and ventilated with peak inspiratory pressures (PIP) of 16 cm H 2 O, PEEP of 2 cm H 2 O at 40 breaths/min and infused with saline containing 0.3 mM bicarbonate ( ± 3 ml / hour ). The left lung transplant was implanted through a left sided thoracotomy. The pulmonary artery and vein of the lung transplant and recipient were anastomosed first. In the left pulmonary vein a small canula, filled with heparin solution, was placed just above the anastomose site (secured with a purse string suture) to facilitate blood sampling for blood gas analysis. Finally the left main bronchus was sutured and surfactant or a bolus of air was instilled.
For surfactant treatment we used Alveofact ®, an organic solvent extracted surfactant from bovine lung ( Thomae GmbH, Biberach, Germany).
Just before reperfusion of the left lung transplant the surfactant (25 mg phospholipids per ml) in a dose of 100 mg/kg body weight (BW) was instilled directly into the main bronchus of the transplant, as described previously (6) . The untreated groups received a bolus of air instead of surfactant. Air instead of saline was used as control because instillation of 1 ml saline caused the death of all five animals ( 6 hour cold ischemia) on ventilator in an earlier performed experiment. Reperfusion of the lung transplant was allowed by releasing the clip on the pulmonary vein first and then that on the pulmonary artery. Warm ischemia time (= ischemia time during implantation ) was 1 hour ± 10 minutes; total lung ischemia times were 6 hours ± 15 minutes or 20 hours ± 30 minutes. After the lung function was measured, the canula in the pulmonary vein was removed, the chest was closed and the rat was weaned from the ventilator.
Sham operation
The sham operation was similar to the recipient operation including limited dissection of tissue around the hilus but without transplantation of the left lung. The sham-operated rats were used as controls for the recovery of surfactant from surgical injury without ischemia-reperfusion.
Symptoms of Reimplantation Response
Immediate lung function. The immediate effect of transplantation injury after 25 minutes of reperfusion was assessed by the A-a O 2 gradient in the left lung, the blood flow in the left pulmonary artery and by the peri-operative mortality. Five minutes before blood was taken from the left pulmonary vein for gas analysis, we suctioned the tube and trachea to remove excessive lung fluids and ventilated the lung 4 times with an increased maximum pressure of 30 cm H 2 O to fully expand the lung. The PO 2 and PCO 2 were measured with a blood gas analyzer (ABL 330, Radiometer, Copenhagen, Denmark). The alveolar-arterial O 2 gradient (A-a O 2 = P A O 2 -P a O 2 ) was calculated using the alveolar gas equation to determine the alveolar PO 2 (P A O 2 ). 
Mortality.
To wean the rat from the ventilator the PIP, PEEP, and frequency were gradually decreased and the FiO 2 lowered to 0.3. In some cases the lung transplantation procedure led to the death of the animal during the weaning procedure or shortly thereafter. The mortality was used as an immediate measure of the severity of the transplantation injury .
Chest roentgenograms.
To assess recovery from transplantation injury we used a ventilation score (9) of chest roentgenograms taken at days 2, 5 and 7 after transplantation. To ascertain a good contrast a short exposure time ( 0.06 sec) and a mammografy film was used. Two investigators blinded for the experimental conditions but not for the day after transplantation or sham operation scored the chest roentgenograms. The score, indicating the degree of ventilation, was the summation of 2 scores and ranged from 0 to 6: one score for aerated surface area (3 = totally -2/3 aerated, 2 = 2/3 -1/3, 1 = 1/3 -minimal, 0 = not aerated) and a second score for lung density ( 3 = normal, 2 = slightly or patchily increased, 1 = moderately increased, and 0 = opaque).
Lung function at one week.
At one week gas exchange, dynamic compliance and pulmonary perfusion were measured. For these measurements the animals were anesthetized with chloralhydrate i.p., intubated and ventilated with FiO 2 = 1, at 24 cm H 2 O PIP, 5 cm H 2 O PEEP, and a frequency of 55 breaths/min. After 10 minutes of ventilation the dynamic compliance of both lungs was determined and blood was drawn from the left ventricle to measure the PO 2 and PCO 2 . The dynamic compliance of both lungs was calculated as: Vmax/24 cm H 2 O/(kg BW donor + kg BW recipient)/ 2, where Vmax is the volume at 24 cm water pressure. Due to adhesions it was impossible to dissect the left lung for separate function measurements without severely damaging the lung; therefore the measured dynamic compliance is the total of left and right lungs. The left lung transplant perfusion was measured by intravenously injected Tc191 labeled macro-aggregates and expressed as percentage counts of total counts (9).
Injury variables in BALF.
After measurement of the lung function at one week, heart and lungs were taken out en-block and left and right lungs were lavaged separately for 5 times with ice-cold saline as described previously (5) . The BAL fluid (BALF) was collected on ice and the total recovered volume noted. Most untreated 20-h ischemia left lung transplants had to be lavaged with smaller volumes than normal to prevent rupture of these lungs. This resulted in a recovered mean volume of 40.8 ± 11.1 ml/kg for the untreated 20-h ischemia group and 54.4 ± 5.8 ml /kg for all other groups; recovery of the BALF was > 89 % for all groups. Right lungs of all groups were lavaged with a mean volume of 101 ± 9.2 ml/kg. The percentage of PMN's and the amount of alveolar proteins in BALF were used as indicators of transplantation injury. Alveolar cells were isolated from BALF by centrifugation at 150 g for 10 min at 4 0 C. PMN's were differentiated from alveolar macrophages and lymphocytes on stained cytospin preparations. In the remaining cell-free BALF the total amount of alveolar proteins was measured according to Lowry modified by adding SDS (12) . This cell-free BALF was also used for surfactant determinations.
Pulmonary Surfactant at one week.
Surfactant in BALF.
To analyze the properties of pulmonary surfactant we assessed its composition in four ways: the total amount of surfactant phospholipids, the percentage of heavy subtype surfactant, the percentage PC of total phospholipids, and the amount of SP-A; in addition we measured the surface tension lowering properties of surfactant in vitro . The amount of phospholipids was measured with a perchloric acid method (13) after lipid extraction (14) . The amount of total phospholipids was calculated by summation of the amounts of phospholipids of the heavy and light subtype fractions of a 1 ml BALF sample after these fractions were separated by centrifugation at 40,000 g for 15 minutes as described previously (6) . To determine the composition of surfactant phospholipids, the remainder of BALF was centrifuged overnight at 100,000 g, 4 o C, to concentrate all the surfactant in a pellet. The phospholipids in the pellet were separated by thin layer chromatography according to Touchstone with solvent E (15). The amount of SP-A in a sample of the BALF was assessed with a sandwich ELISA method (16) . The measured amounts of SP-A represent endogenous SP-A of the lung transplant since the instilled surfactant contains no SP-A. For in vitro surface tension measurements the pelleted surfactant was extracted with chloroform-methanol and resuspended in saline with 20 mM CaCl 2 to a final concentration of 2 mg phospholipids per ml as described previously (6) . Using this purification protocol the final suspension contains the surfactant phospholipids and the hydrophobic surfactant proteins SP-B and SP-C. The surface tension of the surfactant suspension was analyzed in a pulsating bubble surfactometer (Electronetics Corporation, Amherst, NY) according to Enhorning (17) . We used γ at Rmin, the minimum surface tension, at 20 pulsation's and 37 o C as the variable of in vitro surfactant function. In the untreated 20-h ischemia group the score was lower than in the sham control group throughout the week (* p < 0.05) and also lower than the surfactant treated 20-h ischemia group ( † p < 0.05). Data are given as medians, error bars indicate minimum or maximum scores given in a group.
Statistical analysis
For comparison between ventilation scores of the different groups the MannWhitney -U Sum Rank-test was performed. All the other data of the different groups were assessed by single factor ANOVA. Differences with a p-value of < 0.05 were considered statistically significant. 
Results
Lung transplant injury and recovery
Immediately after transplantation, acute lung injury was seen as severe lung dysfunction. At 25 minutes after reperfusion the A-a O 2 gradient and blood flow were abnormal in both untreated groups compared to the sham group (Table 1) . Surfactant treatment improved both the A-a O 2 gradient (p= 0.06) and blood flow in the 6-h ischemia group, but not in the 20-h ischemia group (Table 1 ). The total mortality was 36 % without a significant influence of ischemia time or surfactant treatment ( Table 1 ). The mortality occurred exclusively during the first post-operative hour, and in animals that showed severe injury after 25 minutes of reperfusion as measured by an A-a O 2 gradient over 70 kPa. The chest roentgenograms of the transplanted and sham-operated rats showed initial injury and then a gradual recovery of the lungs during the week (Figure 1 ). On the first roentgenogram, taken two days after operation, all lungs were graded lower than the normal ventilation score of 6. In particular the untreated transplants scored poorly, but even sham-operated lungs were abnormal. On day five, lungs in all groups scored slightly better and continued to improve on the roentgenograms at 1 week. Then, most transplants only showed small radiographic infiltrates, except for lungs in the untreated ischemia groups, of which the 20-h ischemia lungs scored consistently lower than the sham-operated lungs. Importantly, surfactant treatment had significantly increased the ventilation score in the 20-h ischemia group. (Table 2) . Only in the untreated 20-h group the A-a O 2 gradient and dynamic compliance of both lungs remained lower than in the sham-operated group. In the 20-h ischemia group surfactant treatment resulted in a significantly higher dynamic compliance of both lungs , in parallel with the higher ventilation score of the lung transplants. The perfusion was reduced in all transplants, without obvious influence of ischemia or surfactant treatment. Symptoms of persistent lung injury in the transplants as measured by amounts of alveolar protein and % PMN in BALF were absent; the values were as low as in normal rats (Table 2) .
Pulmonary surfactant
Strikingly, we found that without treatment, surfactant in the transplanted left lungs was still abnormal at one week after operation (Table 3) . Generally, surfactant changes were more severe in the 20-h ischemia group than in the 6-h group, and least severe in the sham-operated group. The amount of surfactant phospholipids was significantly lower in these untreated transplanted groups; the proportion heavy subtype was low but within normal range, and the percentage PC was normal ( Table 3 ). The amount of SP-A was significantly lower in the transplanted groups but not in the sham-operated group. The changes in surfactant after transplantation did not impair the in vitro biophysical function of surfactant extracted from BALF; the minimum surface tension of surfactant was in the normal range ( Table 3) . (Table 3) . Surfactant treatment resulted in a slightly higher SP-A amount in both the 6 and 20-h ischemia groups, but the large variation in lung injury within each transplantation group prevented a significant improvement (Table 3) . When analyzing this variation, it appeared that the amount of SP-A at one week correlated strongly with the initial acute injury at the time of reperfusion expressed by the A-a O 2 gradient (Figure 2 ). This correlation, including surfactant-treated and untreated transplants, was highly significant (p < 0.000001). The in vitro biophysical function of surfactant remained normal (Table 3) . Surfactant phospholipids from the right native lungs of the transplanted and sham-operated animals were virtually normal with a slight decrease of proportion of heavy subtype surfactant in all operated groups (data not shown). Strikingly, however, in both the untreated and surfactant treated 20 h ischemia group, an isolated significant lower amount of SP-A in right lungs to 40 % of normal values was measured ( 82.3 ± 18.4 , and 78.4 ± 7.8 vs. 197.6 ± 51.3 µg/kg, respectively, p< 0.01 ). 
Discussion.
Previous studies have shown that pulmonary surfactant is affected early during the reimplantation response after lung transplantation (4-6, 10). The surface-active surfactant components of surfactant, such as its heavy subtype, PC, and SP-A were decreased, which impaired its in vitro biophysical function (4) (5) (6) 10) . This impairment is aggravated in vivo by leaked serum proteins. The present study shows that pulmonary surfactant at one week after transplantation is still deficient. In the untreated 6 h ischemia group the total amount of surfactant phospholipids was only two-third of normal and the amount of SP-A only half of normal; the relative amounts of heavy subtype and PC were normal. Strikingly, the function of lung transplants in the untreated 6 h ischemia group had recovered almost completely from the reimplantation response. In the 20-h ischemia group the total amount of surfactant phospholipids was further decreased to a third and the amount of SP-A to a quarter of normal as an effect of the more severe transplantation injury. In this group the lung transplants still showed features of the reimplantation response: abnormal chest-X-ray, impaired gas exchange, and a low dynamic compliance of both lungs. In sham-operated rats, ventilation without ischemia-reperfusion had no significant effect on pulmonary surfactant. Thus, pulmonary surfactant has not fully recovered from the transplantation injury at one week after syngeneic lung transplantation even in lungs in which the reimplantation response apparently is resolved. The deficient amounts of surfactant phospholipids and SP-A at one week might be caused by the immediate transplantation injury of surfactant producing type II pneumocytes after transplantation. Semik et al found that the type II cells in rat lung transplants were depleted from surfactantcontaining lamellar bodies up to one week after transplantation (18) . These authors hypothesized that this depletion was caused by a deficient synthesis of surfactant after transplantation, which hypothesis would also explain the low alveolar amounts of surfactant in our present study. How the function of type II cells is affected by transplantation injury might be explained in two ways. First, as shown in other lung injury models, type II cells start to proliferate in response to injury of type I cells. These proliferating type II cells have a decreased lamellar body pool size (19) which is consistent with a decreased synthesis of surfactant. Second, production or secretion of phospholipids and SP-A by type II cells can be impaired by reactive oxygen metabolites and cytokines (20) (21) (22) (23) which are generated after lung transplantation (24, 25) . Both these mechanisms may have induced the changes of surfactant that we measured at one week after the initial transplantation injury in the present study.
The present study also shows that treatment with surfactant, instilled as a single dose before reperfusion, increased the surfactant phospholipids to normal amounts at one week after lung transplantation. This normal amount of surfactant might consist merely of instilled surfactant, however, in other acute lung injury models a significant amount of instilled surfactant is quickly metabolized by type II cells or cleared by macrophages (3). Another explanation is that the instillation of surfactant preserves the production of surfactant. This explanation is supported by the study of Semik et al showing that depletion of lamellar bodies in type II cells during the transplantreperfusion period is prevented by surfactant treatment (18) . In conclusion, the persistent normal amount of surfactant phospholipids after surfactant treatment in our lung transplants might be the result of both suppletion and a preserved surfactant metabolism.
Interestingly, surfactant treatment did not only improve surfactant amounts, but also enhanced the recovery from transplantation injury; the ventilation score, the A-a O 2 gradient and the dynamic compliance improved to sham control values. One can think of two ways in which surfactant treatment improved lung function at one week. First, the higher amount of alveolar surfactant might have resulted in a more widespread stabilization of alveoli, thereby improving lung function. Second, the high amount of exogenous surfactant may have suppressed the inflammation process that is provoked by ischemia-reperfusion. Such an anti-inflammatory capacity of surfactant has been shown in vitro and in in vivo (lung) injury models (26) . Apparently, the effect of surfactant instillation remained locally, that is in the alveolar compartment of the lung, as lung perfusion was not improved. We did not assesses whether this low perfusion was due to abnormalities in the pulmonary artery or in the arterioles. Despite the absent effect on lung perfusion, one dose of surfactant before reperfusion clearly improves the recovery of lung transplants from serious transplantation injury.
It seems not so surprising that our surfactant treatment had no effect on SP-A because the instilled surfactant contained no SP-A. Yet, in a previous study instilled surfactant preserved the amount of endogenous SP-A as measured one hour after reperfusion. This preservative effect was attributed to the instilled surfactant phospholipids which were thought to minimize the breakdown of SP-A by products of activated PMN's (6). The low amounts of SP-A at one week after transplantation seems not to correlate with ongoing SP-A breakdown caused by PMN's because few PMN's were present in BALF ( Table 3 ) . Instead, the observed correlation between increased severity of immediate transplantation injury and low amounts of SP-A at one week after injury (Figure 2 ) might indicate that besides initial SP-A breakdown also the SP-A producing type II cells (and Clara cells) are damaged. This theory of an impaired SP-A production is in agreement with the clinical finding that, for more than a year after transplantation, the amount of SP-A is still low in lung transplant patients (27) . This persistently low SP-A level might be of relevance for the local anti-bacterial defense (3) of transplanted lungs.
Few patients have been treated with surfactant after lung transplantation. One report supports the experimental data that it is a useful treatment in early graft failure (28) . Especially prevention of graft failure after prolonged ischemia times might prove to be successful clinically. A promising way of surfactant treatment is to treat first the donor and then again the lung transplant just before reperfusion (29) .
Conclusion
The present study shows, first, that surfactant is not fully recovered at one week after transplantation even in lungs which have recovered apparently from transplantation injury. Second, this study shows that early surfactant treatment in lung transplantation enhances recovery from transplantation injury and has persistent beneficial effects on pulmonary surfactant.
Abstract
This study investigated whether surfactant protein-A (SP-A) enriched surfactant used for treatment of lung transplants in rats could improve the effect of the surfactant treatment. Left lung grafts were kept inflated with 50 % O 2 during 20-h ischemic storage and were transplanted syngeneically in rats. Surfactant (n = 6) or SP-A enriched surfactant (n = 6) was instilled into the left main bronchus of the lung transplant just before reperfusion. Air was instilled into untreated lung transplants (n= 6). Sham operated animals (n = 4) and normal animals (n = 8) served as controls. Lung function was measured for 1 h after reperfusion. Then the rats were killed and broncho-alveolar lavage performed to measure alveolar surfactant components. We found that addition of SP-A to surfactant did not improve the effect of surfactant treatment: neither dynamic compliance nor blood gasses improved as compared to treatment with surfactant without SP-A. Unexpectedly, the function of untreated transplants equaled that of the two surfactant treated groups. Both instillation of surfactant and instillation of SP-A enriched surfactant did increase the amount of surfactant phospholipids and of endogenous rat SP-A. We hypothesize that the absent improvement of transplant function after instillation of surfactant or SP-A enriched surfactant was due to an inadequate spreading of the surfactant in the inflated-stored lung. Other surfactant delivery methods, such as nebulization, may be more effective.
The injury caused by transplantation of lungs leads to dysfunction of pulmonary surfactant (1) (2) (3) . This surfactant dysfunction impairs the function of lung transplants after reperfusion. To improve the function of the injured lung transplants instillation of surfactant has proved to be beneficial. However, not all of the treated lung transplants responded positively to the surfactant treatment (3, 4) . One of the causes for this inconsistent effect of surfactant treatment might be its susceptibility for inactivation by serum proteins. Treatment of lung transplants with a composition of surfactant that is able to resist inhibition of serum proteins might thus improve the effect of treatment.
All surfactants currently used for treatment are susceptible to serum protein inactivation. In this respect the modified natural surfactants, which still contain the hydrophobic surfactant proteins SP-B and SP-C, are probably less susceptible to serum protein inactivation than the protein deficient synthetic exogenous surfactants (5, 6) . Importantly, all the clinically used surfactants lack the hydrophilic surfactant protein A (SP-A), while SP-A is the component of surfactant that in particular counteracts the inactivation of surfactant by serum proteins (7, 8) . Since SP-A enriched surfactant performed better than SP-A deficient surfactant in an other lung injury model (9), we hypothesized that lung transplants also might benefit from treatment with SP-A enriched surfactant.
In the present study the question was asked whether addition of SP-A to exogenous surfactant for treatment of lung transplants improved the effect on lung function and composition of pulmonary surfactant. This was investigated in left lung transplants after 20 h cold and inflated storage and 1h reperfusion in rats.
Materials and methods
Experimental groups and animals
For the experiments inbred rats ( LEW strain, male, 240-320 g, specific pathogen free) were used. All animals received humane care in compliance with the Dutch regulations and law. Five groups of rats with different treatments were investigated: group 1. instillation of surfactant in left lung transplants (n=6), group 2. instillation of SP-A enriched surfactant in left lung transplants (n=6), group 3. instillation of air in left lung transplants (untreated) (n=6), group 4. no treatment of left lung after left sided thoracotomy (sham) (n=4), and, group 5. no treatment and no operation (normal) (n=8). All left lungs were stored for 20 hours at 8 o C after inflation with 50 % oxygen.
Operation: donor, recipient and sham. Left single lung transplantation was performed as previously described (3), with the modification that left lung transplants were stored inflated instead of deflated. The left lung transplant was taken from the donor after a pulmonary artery flush with 25 ml cold (8 o C) saline at 40 cm water pressure, while ventilating the lung with a positive-end-expiratory-pressure (PEEP) of 4 cm H 2 O, a peak inspiratory pressure (PIP) of 12 cm H 2 O, and 50 % oxygen. Next the main left bronchus was clipped at a lung pressure of 10 cm H 2 O, and the inflated lung was submersed in cold saline and placed in the refrigerator at 8 o C for 19 hours. One hour before the start of reperfusion, the lung was taken from the refrigerator and covered with a thin plastic sheet to prevent desiccation during the implantation procedure. The recipient was ventilated using PIP of 12 cm H 2 O, PEEP of 2 cm H 2 O, 100 % oxygen, and 40 breaths/min. Access to the left lung was obtained by a left thoracotomy. After the pulmonary artery and vein were clamped with one large vessel clamp and the left bronchus was ligated, the left lung was removed. For implantation of the left lung transplant the pulmonary artery and pulmonary vein were anastomosed first. To facilitate the sampling of blood for gas analysis, a small canula filled with heparin solution was placed in the left pulmonary vein just distal to the anastomosis site and secured with a purse string suture. To test the sutures of the anastomosis a small vessel clip was placed on the pulmonary artery and vein near to the lung, then the large vessel clamp was removed. Finally, the left main bronchus was sutured and surfactant or a bolus of air was instilled ( see Surfactant treatment below). Reperfusion of the lungs was allowed only after ventilation was started with a PEEP of 5 cm water pressure to prevent the formation of edema. Warm ischemia time (i.e. the ischemia time during the implantation procedure ) was 1 hour ± 10 minutes; total lung ischemia times were 20 hours ± 25 minutes. Sham operated animals were handled in a similar way as recipient rats with the difference that the left lung was not removed. To facilitate placement of a blood flow probe later in the procedure minimal dissection around the pulmonary artery was performed. Then, the ventilatory PEEP was raised to 5 cm H 2 O for 60 minutes like in the transplantation groups. Blood for blood gas measurement of the sham operated animals was drawn from the left ventricle.
Surfactant treatment
BLES ® (BLES Biochemicals Inc., London, Canada), a commercial modified surfactant, which is extracted with an organic solvent from bovine lung lavage fluid was used for treatment. Besides surfactant phospholipids (95 % heavy subtype surfactant) this extracted surfactant contained also SP-B and SP-C, but not SP-A. The SP-A enriched surfactant contained purified bovine SP-A (7) which was added to BLES (5 % SP-A by weight ) (7) . The surfactants were used in a concentration of 25 mg of phospholipids per ml and were given at a dose of 100 mg per kg BW. The untreated group had air instead of surfactant instilled. Surfactant treatment was given just before reperfusion of the left lung transplant. The surfactant dose was instilled through a canula directly into the left main bronchus. Therefore, the clip on the left bronchus was removed and replaced by a ligature which was pulled round the inserted canula to prevent surfactant leaking into the trachea. Surfactant was administered at 0.2 ml doses followed by an air bolus of 0.5 ml to enhance the spreading of surfactant. After the canula was withdrawn, the ventilation settings were changed to 24 cm H 2 O PIP, 5 cm H 2 O PEEP, and 55 breaths/min. The left lung was ventilated without reperfusion for 1 minute to facilitate spreading of surfactant before the onset of reperfusion injury. Reperfusion of the lung transplant was allowed, by first releasing the clip on the pulmonary vein followed by releasing the clip on the pulmonary artery. To enhance further surfactant spreading by gravity the rat was turned on its left side for the first 5 minutes of reperfusion and then turned back on its right side to allow measurements of lung transplant function.
Lung transplant function
Transplant function was measured during a 1-hour reperfusion period at three time points: 10, 30, and 60 minutes. Transplant function was assessed by measuring PO2 and PCO2 in blood drawn from the left pulmonary vein, dynamic compliance of both lungs, and by measuring blood flow through the left pulmonary artery (only at 60 minutes). Five minutes before a blood gas sample was taken, excessive lung fluids were suctioned from the tube and trachea and PIP was increased to 30 cm H2O during four breaths to expand the lung completely. PO2 and PCO2 were measured with a blood gas analyzer (ABL 330, Radiometer, Copenhagen, Denmark). Dynamic compliance of both lungs at 5 cm H2O PEEP and 24 cm H2O PIP was calculated as follows: Volume (at 24 cm H2O PIP) x 24 cm H2O -1 x ((kg BW donor + kg BW recipient)/ 2)-1. The dynamic compliance of both lungs may not be a sensitive measure for the function of the left lung transplant, but differences between separate groups can be attributed to changes in the left lung transplant. The blood flow was measured with an ultrasound method ( 1 mm probe (1RB), Transonic Systems Inc., Ithaca, NY ). The flow probe was placed round the pulmonary artery immediately after the blood samples for the PO2 and PCO2 at 60 minutes were drawn. In sham operated animals measurements were only performed at 60 minutes.
Bronchoalveolar lavage (BAL) and suction fluid
After the 1-hour reperfusion period the rats were killed by bleeding the animals. Heart and lungs were taken out en-bloc. Left lungs were lavaged as described previously 4 . The total recovered volume was recorded. The recovered BAL volume per kg BW did not differ between the groups (on average 58 ml/kg BW). The BAL fluid (BALF) was centrifuged at 150 g for 10 min. at 4 o C to remove cells and cell-debris. The remaining cell-free BALF was used for all further determinations of BALF. Apart from BALF, suction fluid from the tube and trachea was sampled in 3 surfactant and 3 SP-A enriched surfactant treated rats to measure the loss of surfactant phospholipids.
Pulmonary surfactant
Four components of alveolar surfactant were determined in BALF: the amount of total surfactant phospholipids, the percentage of heavy subtype surfactant, the percentage phosphatidylcholine (PC) of total phospholipids, and the amount of endogenous rat SP-A. The amount of total phospholipid was calculated by summing up the amount of phospholipids in separated light and heavy subtype fractions: heavy and light subtypes were separated by centrifuging a 1 ml sample of the cell free BALF at 40,000 g for 15 minutes (Beckman TL 1000, rotor TLA-100.3 ). After centrifugation the supernatant contains the light subtype and the pellet the heavy subtype. Both supernatant and pellet were extracted with chloroform and methanol (10) to measure phospholipid contents (11) . After samples were taken for SP-A measurements, the cell free BALF was centrifuged overnight at 100,000 g, 4 oC, to concentrate the surfactant for the determination of the phospholipid composition. The phospholipids were separated by thin layer chromatography according to Touchstone with the use of their solvent E (12) . The amount of SP-A in cell free BALF was assessed with a sandwich ELISA method (13) . Note that the measured amounts of SP-A represent only the endogenous rat SP-A of the lung transplants since the bovine SP-A used for instillation can not be detected by the antibodies used in this ELISA. The amount of leaked serum proteins was measured with the method of Lowry (14) . Surfactant from the transplanted groups was compared to surfactant from a normal group instead to surfactant from the sham operated group. The reason for this comparison is that placement and removal of the blood flow probe in the sham operated group is difficult and causes additional damage to the lung and possibly to the pulmonary surfactant.
Statistical analysis
For comparison between the data of the different groups single factor ANOVA was used. To test whether the lung function improved during reperfusion ( 30 or 60 min. compared to 10 min.) a paired student-t test was performed. Values of p < 0.05 were considered to be statistically significant.
Results
Function of lung transplants
Instillation of SP-A enriched surfactant did not improve the blood gasses of left lung transplants as compared to installation of surfactant alone (table 1) . In the contrary, some blood gas values at 10 and 30 minutes after reperfusion in the two surfactant treated groups were worse than blood gas values of the untreated group. Interestingly, the PO 2 at 30 and 60 minutes of reperfusion in the SP-A enriched surfactant instillation group was significantly higher than at 10 minutes of reperfusion (p < 0.05 ) and the PO 2 value at 60 minutes was not significantly different from the sham control PO 2 value. Compliance was not significantly affected by either of the two surfactant treatments and equaled values obtained in the untreated group at 60 minutes of reperfusion. Blood flow was significantly lower in all transplantation groups compared to the sham operated group. 
Pulmonary surfactant
Pulmonary surfactant isolated from the BALF was, in contrast to transplant function, significantly better in lung transplants treated with either surfactant or SP-A enriched surfactant than in untreated transplants (table 2). As might be expected after the high dose instilled phospholipids which was for 95 % in the heavy subtype form, the amounts of surfactant phospholipids and the percentage heavy subtype surfactant was higher in the two surfactant treated groups than in the untreated group. Lower amounts of total phospholipids were recovered in the SP-A enriched surfactant group than in the surfactant group. The suction fluid from both surfactant treatment groups (n = 3 each) contained high amounts of phospholipids: 57.3 ± 9.3 mg/kg BW, being about 60 % of the instilled dose; the amounts were not different between the two treatment groups. The somewhat lower percentage PC in both treatment groups can be explained by the relatively low percentage of PC (74 %) in the instilled surfactant. Unexpectedly, the amount of endogenous rat SP-A remained at a normal level after both surfactant and SP-A enriched surfactant treatment. Protein content was significantly higher in all three transplanted groups compared to normal control values. 
Surfactantcomponents
Discussion
In this study, adding SP-A to a modified natural surfactant did not improve the efficacy of surfactant treatment of lung transplants. Moreover, instillation of surfactant had no obvious beneficial effect on lung transplant function. Previously we have shown clear beneficial effects of surfactant instillation on function of severely injured lung transplants (3). Therefore, we believe that factors related to the inflated storage in the present study might be responsible for the lacking efficacy of surfactant treatment. The factor(s) responsible for the lacking effect of surfactant treatment may also have blurred the effect of adding SP-A to surfactant. Despite the lacking effect on lung function, surfactant treatment of the lung transplants did preserve pulmonary surfactant in BALF including the amounts of endogenous SP-A. Airway obstruction or an insufficient surfactant spreading are most likely the factors responsible for a lacking effect of surfactant instillation in this study with inflated lung storage. Airway obstruction is described to occur after instillation of surfactant in other acute lung injuries (15) . In lung transplantation, Novick and coworkers, (4, 16) also blamed airway obstruction or an insufficient spreading of instilled surfactant for an absent improvement of transplant function. In their study instillation of surfactant into inflated stored sheep lungs did not improve blood gasses but necessitate high tidal volumes to keep the PCO 2 within acceptable limits after reperfusion of the transplant. In the present study the PCO 2 rose initially to high levels with a fixed ventilator setting, probably also caused by airway obstruction or insufficient surfactant spreading. Furthermore, the excessive loss of instilled surfactant measured in the suction fluid of the tube and trachea ( about 58 % of total instilled) indicates a lack of spreading. We therefore think that an inflated state of the lung during surfactant instillation does not promote an adequate surfactant spreading. This speculation is in line with findings of Cummings and coworkers, (17) who showed that surfactant instillation in surfactant deficient lungs from premature lambs was more successful when instilled in unventilated, collapsed, lungs than in ventilated lungs. We hypothesize that complete collapse of an inflated-stored lung just before instillation of surfactant may improve the surfactant spreading and, consequently, the effect of surfactant treatment.
Another way to improve the effect of surfactant treatment using inflated lung storage can be achieved by nebulization instead of instillation of surfactant. As shown by Novick and collaborator's, (16) nebulization of surfactant into a ventilated lung donor improved the function of the inflated stored lung transplant, whereas instillation of surfactant just before reperfusion had no effect. Remarkably, when nebulization of surfactant into the lung donor was combined with instillation of surfactant just before reperfusion the effect of surfactant treatment was optimal, reflected by blood gas values at pre-operative levels (16) . The mechanism of this excellent effect after the combined delivery of surfactant might be that the film of surfactant in the lung that remains after nebulization enhances the spreading of the later instilled surfactant (18) .
A beneficial effect of surfactant treatment may also become evident after a longer period of reperfusion and ventilation. As shown by others, only after 3 hours of reperfusion, instillation of surfactant resulted in an improved gas exchange (4) . This long period of reperfusion and mechanical ventilation might have been necessary for resolving obstruction and spreading of surfactant. The increasing PO 2 in the SP-A enriched surfactant group during the 1 h reperfusion period is in line with this speculation. However, to prevent barotrauma to the lung cells during mechanical ventilation, caused by compliance differences in alveoli due to the inadequate surfactant spreading (19) , an immediate effect is important.
Surfactant instillation preserved surfactant composition and increased the amount of surfactant in BALF. Most interesting is the preservation of endogenous rat SP-A at a normal level after both surfactant treatments. SP-A is thought to protect the surfactant monolayer for interference by leaked serum proteins. The high level of SP-A after treatment with the modified surfactant alone might explain why enrichment with SP-A did not result in a better effect. Furthermore, this finding is in line with our previously stated hypothesis that surfactant treatment protects endogenous SP-A against damage caused by ischemia-reperfusion (3).
Conclusion
In this study instillation of surfactant enriched with SP-A did not improve lung transplant function after a 1 hour reperfusion period. Importantly however, it is confirmed that early surfactant treatment does improve surfactant phospholipid composition and preserves SP-A after reperfusion. We believe that after inflated lung storage instead of instillation of surfactant other delivery techniques, such as nebulization, will improve surfactant spreading and, as a consequence, improve the immediate lung transplant function . In such a situation the effect of enrichment of surfactant with SP-A can be investigated more properly.
